CTOs on the Move

MASA MTS

www.masamts.com

 
MASA Medical Transportation Solutions is a company that provides emergency medical transportation services and protection from high emergency medical transportation costs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.masamts.com
  • 1250, South Pine Island Road
    Plantation, FL USA 33324
  • Phone: 877.503.0585

Executives

Name Title Contact Details

Similar Companies

Freespira

Freespira® is an FDA-cleared digital therapeutic proven to significantly reduce or eliminate Panic Disorder and PTSD symptoms by training users to normalize respiratory irregularities in just 28 days. Health plans, self-insured employers and the Veteran`s Administration use the company`s drug-free solution to improve quality of life, reduce medical spending and support the appropriate use of valuable healthcare resources.

NarrativeDx

NarrativeDx is the artificial intelligence platform for patient experience. Our SaaS platform is the market leader in transforming hospitals` clinical outcomes by extracting data trends and gaining visibility into the patient experience. We help hospital leaders and care providers understand and improve their institution`s patient experience, drive patient referrals, increase hospital revenue, and boost hospital reputations.

MedSource Consulting

MedSource Consulting is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Resolution Health Strategies

Resolution Health Strategies is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.